Intuitive’s US da Vinci procedure growth slows again
Intuitive Surgical reported Q3 revenue of $3.05B, up 22% YoY, with net income of $523M. U.S. da Vinci procedure growth slowed to 10%, the lowest since the pandemic. CEO David Rosa cited adoption challenges in benign general surgery. The company cut instrument prices to boost adoption in high-volume procedures, reducing near-term revenue per procedure. Intuitive adjusted its 2026 da Vinci procedure growth forecast to 14-15%.
How this was made
The 30-second read
Why it matters
The guidance downgrade may trigger a sell‑off, but pricing strategy could improve volume later.
Market read
Earnings and guidance update for a large‑cap med‑tech company; likely short‑term price impact.
What to watch
Potential upside from new indications and international market expansion.
Background
Intuitive Surgical reported Q3 results with slower U.S. da Vinci procedure growth and revised 2026 guidance.
Ticker impact
Q3 revenue $3.05B, da Vinci procedure growth slowed to 10% and guidance reset to 14‑15% for 2026.
likely downside as investors price in slower growth and lower instrument revenue.
Guidance reduction is a material change; analysts will likely downgrade forecasts, prompting sell pressure.
Market effects
Robotics and medical device sector may see broader concerns about procedure adoption rates.
U.S. hospital procurement outlook could be tempered.
Limited to Intuitive; no immediate global macro effect.
Counterpoint
Pricing cuts could boost long‑term adoption, supporting a rebound.
Key entities
- ExecutiveDavid Rosa
CEO of Intuitive Surgical
- ExecutiveJamie Samath
CFO of Intuitive Surgical
